Madsen Steen, Hirschberg Henry
Department of Health Physics, Las Vegas Cancer Research Center, University of Nevada, Las Vegas, NV 89154-3037, USA.
J Environ Pathol Toxicol Oncol. 2006;25(1-2):453-66. doi: 10.1615/jenvironpatholtoxicoloncol.v25.i1-2.290.
The first reported use of photodynamic therapy (PDT) for the treatment of high-grade gliomas occurred in 1981. In the intervening years there have been relatively few clinical trials to investigate the efficacy of this therapeutic modality for the treatment of gliomas. This is due, in part, to the rarity of the disease, and the ever growing list of novel therapies that PDT must compete against. These factors make accrual of patients for clinical trials a difficult proposition. During the mid-1990s, a number of reviews were published that effectively summarized the status of PDT for the management of high-grade gliomas. The intent of the present work is to provide an update of recent developments (1996-2004) in PDT and photodynamic detection (PDD) of gliomas, in particular, glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA).
首次报道使用光动力疗法（PDT）治疗高级别胶质瘤发生在1981年。在这期间，相对较少有临床试验来研究这种治疗方式对胶质瘤治疗的疗效。部分原因在于该疾病的罕见性，以及光动力疗法必须与之竞争的不断增加的新型疗法列表。这些因素使得招募患者进行临床试验成为一个难题。在20世纪90年代中期，发表了一些综述，有效地总结了光动力疗法治疗高级别胶质瘤的现状。本研究的目的是提供关于胶质瘤，特别是多形性胶质母细胞瘤（GBM）和间变性星形细胞瘤（AA）的光动力疗法（PDT）和光动力检测（PDD）的最新进展（1996 - 2004年）。
